Inhibikase Therapeutics Stock Analysis

Inhibikase Stock Analysis Notes

The company recorded a loss per share of 3.12. Inhibikase Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 30th of June 2023. Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Inhibikase Therapeutics call Milton Werner at 678 392 3419 or check out https://www.inhibikase.com.

Inhibikase Therapeutics Investment Alerts

Inhibikase Therapeutics Upcoming and Recent Events

Inhibikase Largest EPS Surprises

View All Earnings Estimates

Inhibikase Stock Institutional Investors

Note, although Inhibikase Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Inhibikase Market Capitalization

The company currently falls under 'Small-Cap' category with a total capitalization of 133.18 M.

Inhibikase Profitablity

Management Efficiency

Inhibikase Therapeutics has Return on Asset of (0.7621) % which means that on every $100 spent on assets, it lost $0.7621. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.4969) %, meaning that it generated no profit with money invested by stockholders. Inhibikase Therapeutics' management efficiency ratios could be used to measure how well Inhibikase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.24 in 2025. Return On Capital Employed is likely to gain to -1.98 in 2025. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2025.

Technical Drivers

As of the 31st of January, Inhibikase Therapeutics retains the Standard Deviation of 7.33, market risk adjusted performance of 0.1307, and Risk Adjusted Performance of (0.01). Inhibikase Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Inhibikase Therapeutics Price Movement Analysis

Inhibikase Therapeutics Insider Trading Activities

Inhibikase Therapeutics Outstanding Bonds

Inhibikase Therapeutics Predictive Daily Indicators

Inhibikase Therapeutics Forecast Models

Inhibikase Therapeutics' time-series forecasting models are one of many Inhibikase Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inhibikase Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Inhibikase Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Inhibikase shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Inhibikase Therapeutics. By using and applying Inhibikase Stock analysis, traders can create a robust methodology for identifying Inhibikase entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inhibikase analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inhibikase analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Inhibikase Therapeutics stock analysis indicators help investors evaluate how Inhibikase Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Inhibikase Therapeutics shares will generate the highest return on investment. By understating and applying Inhibikase Therapeutics stock analysis, traders can identify Inhibikase Therapeutics position entry and exit signals to maximize returns.

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.